Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. (Q38936367)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. |
scientific article |
Statements
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial (English)
J Randolph Hecht
Shukui K Qin
Jianming M Xu
Joon O Park
Yaroslav Shparyk
Paulo M Hoff
Alberto Sobrero
Pamela Salman
Jin Li
Svetlana A Protsenko
Zev A Wainberg
Marc Buyse
Karen Afenjar
Vincent Houé
Agathe Garcia
Tomomi Kaneko
Yingjie Huang
Saba Khan-Wasti
Sergio Santillana
Michael F Press
30 November 2015